Nasdaq:BGLC
BioNexus Gene Lab Corp
A biotech firm specializing in genetic lab services that recently achieved profitability with $1.6M net income and stable revenue amidst industry growth.
Key Metrics
Investment Thesis
Bull Case
BGLC presents a compelling turnaround story with a confirmed shift from deep losses to positive net income in 2024, indicating improved operational efficiency and cost control. The company's ability to generate positive financing cash flow of $144,975 while reducing accumulated deficits suggests a solid foundation for future expansion without immediate need for dilutive equity issuance.
Bear Case
Investors should be cautious due to persistently negative operating cash flow of -$2.2M and a retained earnings deficit of -$3.4M, which indicates ongoing liquidity pressures despite reported accounting profits. The decline in revenue over three years combined with high general and administrative expenses relative to gross profit suggests underlying business model fragility.
About BioNexus Gene Lab Corp
BioNexus Gene Lab Corp (BGLC) operates within the biotechnology and genetic testing sector, providing specialized laboratory services and diagnostic solutions to healthcare providers and research institutions. The company has demonstrated a significant turnaround in profitability, shifting from substantial losses in previous years to generating net profit of $1.6M in 2024 while maintaining revenue stability near $9.5M. With strong cash flow from financing activities and reduced current liabilities, BGLC is positioning itself as a resilient player in the growing genomic medicine market.
Analysis
Management Discussion
The company successfully navigated a challenging period with declining revenue from $10.9M in 2022 to $9.5M in 2024, yet engineered a dramatic profitability turnaround by turning net loss of -$2.6M into a $1.6M profit. Despite negative operating cash flow of -$2.2M and significant non-cash adjustments of -$4.1M, the firm strengthened its balance sheet with ending cash at $2.9M and total assets growing to $10.4M.
Industry Overview
The genetic testing industry is experiencing rapid growth driven by advancements in sequencing technology and increasing demand for personalized medicine, yet faces regulatory headwinds and pricing pressure from payers. Companies in this space must balance high R&D investments with the need to maintain profitability margins as competition intensifies among mid-cap biotech firms.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | $10.9M | $9.8M | $9.5M |
| Cost of Revenue | $9.7M | $8.4M | $8.2M |
| Gross Profit | $1.3M | $1.3M | $1.3M |
| Operating Expenses | $1.6M | $3.9M | $-4.9M |
| Operating Income | $-291.2K | $-2.6M | $-1.6M |
| R&D | — | — | $47.5K |
| G&A | $1.7M | $4.4M | $2.0M |
| Marketing | — | — | $2.0M |
| Depreciation | $91.4K | $83.3K | $104.2K |
| Other OpEx | $-179.3K | $-486.0K | $-9.0M |
| Non-Operating Income | $-12.5K | $-13.9K | $-21.1K |
| Interest Expense | — | $13.9K | — |
| Interest Income | — | — | $147.6K |
| Pre-Tax Income | $-303.7K | $-2.6M | $-1.6M |
| Income Tax | $-52.3K | $-21.5K | $-3.5K |
| Continuing Ops | $-251.3K | $-2.6M | $-1.6M |
| Discontinued Ops | $-104.6K | $-43.1K | $3.2M |
| Net Income | $-356.0K | $-2.6M | $1.6M |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $-356.0K | $-2.6M | $1.6M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Current Assets | $6.0M | $8.0M | $7.4M |
| Inventory | $977.8K | $1.1M | $1.4M |
| Other Current Assets | $5.0M | $6.9M | $6.0M |
| Long-Term Assets | $2.7M | $3.4M | $3.0M |
| PP&E (Net) | $1.5M | $1.5M | $1.5M |
| Operating Leases | $55.7K | $141.5K | $215.2K |
| Other LT Assets | $1.2M | $1.7M | $1.3M |
| Total Assets | $8.7M | $11.4M | $10.4M |
| Current Liabilities | $2.0M | $1.6M | $2.0M |
| Accounts Payable | $1.9M | $1.4M | $1.5M |
| Current Leases | $16.6K | $34.6K | $50.8K |
| Other Current Liab | $126.5K | $194.1K | $397.2K |
| Long-Term Liabilities | $71.1K | $111.0K | $159.7K |
| LT Operating Leases | $40.2K | $98.8K | $159.7K |
| Other LT Liab | $30.9K | $12.3K | $0 |
| Total Liabilities | $2.1M | $1.7M | $2.1M |
| Shareholders' Equity | $6.7M | $9.7M | $8.3M |
| Paid-In Capital | $-5.0M | $-5.0M | $-5.0M |
| Retained Earnings | $1.2M | $-1.8M | $-3.4M |
| AOCI | $-409.1K | $-677.3K | $-555.0K |
| Total L&E | $8.7M | $11.4M | $10.4M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Net Income (CFO) | $-356.0K | $-2.6M | $1.6M |
| Non-Cash Adjustments | $134.2K | $1.2M | $-4.1M |
| Working Capital Changes | $765.8K | $118.0K | $257.3K |
| Cash from Operations | $544.0K | $-1.3M | $-2.2M |
| Capital Expenditures | $54.2K | $18 | $227.0K |
| Cash from Investing | $-450.5K | $-382.6K | $418.2K |
| Cash from Financing | $116.0K | $5.8M | $145.0K |
| FX Effect | $-214.5K | $-259.7K | $40.3K |
| Net Change in Cash | $-5.1K | $3.8M | $-1.6M |
| Beginning Cash | $2.1M | $2.1M | $4.5M |
| Ending Cash | $2.1M | $5.9M | $2.9M |
Frequently Asked Questions
How does BioNexus Gene Lab Corp make money?
Core laboratory testing services for clinical diagnostics, specialized research partnerships generating non-operating income of $3.2M from discontinued ops or spin-offs, and proprietary software licensing related to genomic data analysis.
What are the main risks for BGLC?
Regulatory changes in genetic testing standards could impact service pricing and scope, dependence on limited non-controlling interests affecting long-term equity stability, potential volatility in cash flows from operations which remains negative at -$2.2M, and intense competition from larger biotech conglomerates.
What is BGLC's competitive advantage?
Proprietary genetic sequencing technology offering faster turnaround times, strategic partnerships with major healthcare networks ensuring recurring revenue, and a lean operational structure allowing for high gross profit margins relative to total revenue.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.